Citius Pharmaceuticals (CTXR) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for April 6, 2026, to elect seven directors and ratify the selection of Wolf & Company, P.C. as auditor for the fiscal year ending September 30, 2026.

• Proxy materials are distributed electronically to reduce costs and environmental impact.

• Record date for voting is February 13, 2026, with 22,376,427 shares outstanding, each entitled to one vote.

• Voting can be done via Internet, phone, mail, or in person at the meeting.

Voting matters and shareholder proposals

• Shareholders will vote on electing seven directors and ratifying the appointment of Wolf & Company, P.C. as auditor.

• No other shareholder proposals or nominations were submitted for this meeting.

• Procedures for submitting proposals and director nominations for the 2027 meeting are detailed, with deadlines and requirements specified.

Board of directors and corporate governance

• Board consists of seven members, with Leonard Mazur as CEO and Executive Chairman, and Myron Holubiak as Executive Vice Chairman.

• Five directors are independent; Mazur and Holubiak are not due to employment.

• Committees include Audit and Risk, Compensation, and Nominating and Governance, all with independent members.

• Lead Independent Director is Suren Dutia.

• Code of Ethics and Business Conduct applies to all directors, officers, and employees.